Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

Recommendations include use of ACE-I or ARB to slow CKD progression in patients with hypertension and albuminuria.

Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive ...

Primary aldosteronism management depends on a multitude of factors, and surgical adrenalectomy is generally recommended in ...

Financial Guidance As of September 30, 2025, cash, cash equivalents and investments totaled $413.0 million, which the company expects will be sufficient to fund its operating plan into 2H 2028, beyond ...

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is ...

Roy Mathew, MD, discusses integrating nephrology and cardiology to bridge the gap in patient adherence and care delivery. While the pipeline for cardio-renal therapeutics is expanding, clinical ...

Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.

Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal ...

Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that it has submitted a Biologics License ...

In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying e ...

Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its ...